112,95 €*
Versandkostenfrei per Post / DHL
Lieferzeit 4-7 Werktage
Presented in alphabetical order and by drug class, drug interactions that occur between ASMs and also between ASMs and non- ASMs are described in three sections: Drug interactions between ASMs; Drug interactions between ASMs and non- ASM Drugs: Interactions affecting ASMs; Drug interactions between ASMs and non ASM Drugs: Interactions affected by ASMs. The latest data on all drug interactions is presented. New agents discussed include cannabidiol, cenobamate, everolimus and fenfluramine,.
Antiseizure Medication Interactions: A Clinical Guide, 4th Edition concisely presents the most recent developments and data available on the topic. Therefore, enabling physicians and allied health professionals to make more rational choices when ASM polytherapy regimens are required. It will be of interest to medical professionals in disciplines including neurology, psychiatry and pediatrics.
Presented in alphabetical order and by drug class, drug interactions that occur between ASMs and also between ASMs and non- ASMs are described in three sections: Drug interactions between ASMs; Drug interactions between ASMs and non- ASM Drugs: Interactions affecting ASMs; Drug interactions between ASMs and non ASM Drugs: Interactions affected by ASMs. The latest data on all drug interactions is presented. New agents discussed include cannabidiol, cenobamate, everolimus and fenfluramine,.
Antiseizure Medication Interactions: A Clinical Guide, 4th Edition concisely presents the most recent developments and data available on the topic. Therefore, enabling physicians and allied health professionals to make more rational choices when ASM polytherapy regimens are required. It will be of interest to medical professionals in disciplines including neurology, psychiatry and pediatrics.
Philip Patsalos is an Emeritus Professor of Clinical Pharmacology at University College London's Queen Square Institute of Neurology, Department of Clinical and Experimental Epilepsy, London UK. His clinical and research interests relate to the therapeutics of epilepsy and include: new drug treatments and strategies, new drug development (Phase II and III trials) and formulations, pharmacokinetic profiling and drug interactions. He has in excess of 230 publications (books, book chapters and peer reviewed papers) and has served on various International League Against Epilepsy (ILAE) committees (including the Commission on Therapeutic Strategies, the Commission on Generics, the Sub-Commission on Polytherapy and Drug Interaction and the Sub-Commission on Therapeutic Drug Monitoring) and International Association of Therapeutic Drug Monitoring and Clinical Toxicology committees (including the Clinical Pharmacokinetics Committee and the Impact of Therapeutic Drug Monitoring on Pharmacoeconomics Committee). He was recently awarded the 2016 Excellence in Epilepsy Lifetime Achievement Award by the British Branch ILAE for his contribution to epilepsy care and research.
Includes details of the magnitude and mechanism of relevant interactions
Discusses the uses of new agents including cannabidiol and cenobamate
Features relevant data on the topics covered
Erscheinungsjahr: | 2022 |
---|---|
Fachbereich: | Andere Fachgebiete |
Genre: | Mathematik, Medizin, Naturwissenschaften, Technik |
Rubrik: | Wissenschaften |
Medium: | Taschenbuch |
Inhalt: |
xv
357 S. 32 s/w Illustr. 357 p. 32 illus. |
ISBN-13: | 9783030827892 |
ISBN-10: | 3030827895 |
Sprache: | Englisch |
Ausstattung / Beilage: | Paperback |
Einband: | Kartoniert / Broschiert |
Autor: | Patsalos, Philip N. |
Auflage: | 4th ed. 2022 |
Hersteller: |
Springer International Publishing
Springer International Publishing AG |
Verantwortliche Person für die EU: | Books on Demand GmbH, In de Tarpen 42, D-22848 Norderstedt, info@bod.de |
Maße: | 235 x 155 x 21 mm |
Von/Mit: | Philip N. Patsalos |
Erscheinungsdatum: | 02.01.2022 |
Gewicht: | 0,569 kg |
Philip Patsalos is an Emeritus Professor of Clinical Pharmacology at University College London's Queen Square Institute of Neurology, Department of Clinical and Experimental Epilepsy, London UK. His clinical and research interests relate to the therapeutics of epilepsy and include: new drug treatments and strategies, new drug development (Phase II and III trials) and formulations, pharmacokinetic profiling and drug interactions. He has in excess of 230 publications (books, book chapters and peer reviewed papers) and has served on various International League Against Epilepsy (ILAE) committees (including the Commission on Therapeutic Strategies, the Commission on Generics, the Sub-Commission on Polytherapy and Drug Interaction and the Sub-Commission on Therapeutic Drug Monitoring) and International Association of Therapeutic Drug Monitoring and Clinical Toxicology committees (including the Clinical Pharmacokinetics Committee and the Impact of Therapeutic Drug Monitoring on Pharmacoeconomics Committee). He was recently awarded the 2016 Excellence in Epilepsy Lifetime Achievement Award by the British Branch ILAE for his contribution to epilepsy care and research.
Includes details of the magnitude and mechanism of relevant interactions
Discusses the uses of new agents including cannabidiol and cenobamate
Features relevant data on the topics covered
Erscheinungsjahr: | 2022 |
---|---|
Fachbereich: | Andere Fachgebiete |
Genre: | Mathematik, Medizin, Naturwissenschaften, Technik |
Rubrik: | Wissenschaften |
Medium: | Taschenbuch |
Inhalt: |
xv
357 S. 32 s/w Illustr. 357 p. 32 illus. |
ISBN-13: | 9783030827892 |
ISBN-10: | 3030827895 |
Sprache: | Englisch |
Ausstattung / Beilage: | Paperback |
Einband: | Kartoniert / Broschiert |
Autor: | Patsalos, Philip N. |
Auflage: | 4th ed. 2022 |
Hersteller: |
Springer International Publishing
Springer International Publishing AG |
Verantwortliche Person für die EU: | Books on Demand GmbH, In de Tarpen 42, D-22848 Norderstedt, info@bod.de |
Maße: | 235 x 155 x 21 mm |
Von/Mit: | Philip N. Patsalos |
Erscheinungsdatum: | 02.01.2022 |
Gewicht: | 0,569 kg |